Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melflufen + Dexamethasone in Elderly Relapsed Myeloma
NCT06682637Phase 2Withdrawn
- Sponsor
- Fondazione EMN Italy
- Start
- Mar 2025
- Primary completion
- Mar 2025
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of melphalan flufenamide in multiple myeloma (MM), sponsored by Fondazione EMN Italy. Primary endpoint: Overall Response Rate at 6 months. Planned start Mar 2025; status: withdrawn.
02
Drugs
melphalan flufenamide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06682637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06682637.